Shots:
Recently AstraZeneca and Amgen presented the results in late-breaking session from the COURSE trial, a proof-of-concept study evaluating tezepelumab in COPD
The PoC study was carried out in people with moderately to very severe COPD with a broad range of eosinophil levels
Today, at PharmaShots we have Robert Fogel from AstraZeneca, Janet Franklin from…
Shots:
Cardiopulmonary events associated with COPD are responsible for an increasing mortality rate in COPD patients. ETHOS trial, a posthoc analysis navigates BGF’s impact on a wide range of cardiopulmonary outcomes beyond COPD exacerbations
The post-hoc analysis reveals that AstraZeneca’s Breztri led to a 20% reduction in the risk of severe cardiopulmonary events. AstraZeneca is currently…
Shots:
Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM)
Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma
In late 2022,…
Shots:
The EC has approved to 5 Biologics and 3 New Chemical Entities in August 2024, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Johnson & Johnson’s Balversa to treat Metastatic Urothelial Carcinoma (mUC) and Takeda’s Adzynma for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
PharmaShots has compiled a list…
Shots:
Recently, the European Commission approved AbbVie’s Skyrizi for the treatment of adults with moderate to severe active Ulcerative Colitis
The approval was based on positive data from the P-III INSPIRE induction trial and COMMAND maintenance study
Today, at PharmaShots we have Sofie Berg, the therapeutic area head of international immunology, International Medical Affairs, at…
Shots:
Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues
In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved
For a…
Shots:
Transforming care with advanced mechanisms of action, monoclonal antibody therapies hold a strong foothold in the healthcare market
In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Keytruda with $25.01B revenue ranks first in our list followed by…
Previously in PharmaShots Magazine, we explored Companion Animals as a theme. For the September Edition, our theme is centered on livestock animals. Livestock farming remains one of the key sectors in agrarian economies like India, China, and Latin American countries. Livestock farming provides us with milk and meat enriched with essential nutritional compounds like protein. …
Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies.
By leveraging Sapient's real-world data asset, the…
Shots:
An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies
In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com
Established in 1993 in San Francisco, California,…

